ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2011
Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.Public health reports (Washington, D.C. : 1974) · 2013Guideline
- Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures.BMJ case reports · 2023Article
- Prevalence of Blood-Borne Viruses and Predictors of Risk in Potential Organ Donors in Australia.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation.JAMA network open · 2020Article
- Hepatitis C-Positive Donors in Cardiac Transplantation: Problems and Opportunities.Current heart failure reports · 2020Review
- Using machine learning to estimate survival curves for patients receiving an increased risk for disease transmission heart, liver, or lung versus waiting for a standard organ.Transplant infectious disease : an official journal of the Transplantation Society · 2019Article
- Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Article
- Opioid epidemic and liver disease.JHEP reports : innovation in hepatology · 2019Review
- The Opioid Crisis and Its Consequences.Transplantation · 2017Article
- Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Article
- Donor-derived infection--the challenge for transplant safety.Nature reviews. Nephrology · 2014Review
- Encephalitis caused by pathogens transmitted through organ transplants, United States, 2002-2013.Emerging infectious diseases · 2014Article
- Guidance on the use of increased infectious risk donors for organ transplantation.Transplantation · 2014Article
- Expanded criteria donors.Clinics in liver disease · 2014Review
- Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature.Journal of clinical and experimental hepatology · 2013Review
- Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013Article
- Virus NAT for HIV, HBV, and HCV in Post-Mortal Blood Specimens over 48 h after Death of Infected Patients - First Results.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2012Article
- Infectious disease transmission during organ and tissue transplantation.Emerging infectious diseases · 2012Article
- Molecular beacon probes-base multiplex NASBA Real-time for detection of HIV-1 and HCV.Iranian journal of microbiology · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To prevent unintentional transmission of bloodborne pathogens through organ transplantation, organ procurement organizations (OPOs) screen potential donors by serologic testing to identify human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. Newly acquired infection, however, may be undetectable by serologic testing. Our objective was to estimate the incidence of undetected infection among potential organ donors and to assess the significance of risk reductions conferred by nucleic acid testing (NAT) versus serology alone. We calculated prevalence of HIV and HCV-stratified by OPO risk designation-in 13,667 potential organ donors managed by 17 OPOs from 1/1/2004 to 7/1/2008. We calculated incidence of undetected infection using the incidence-window period approach. The prevalence of HIV was 0.10% for normal risk potential donors and 0.50% for high risk potential donors; HCV prevalence was 3.45% and 18.20%, respectively. For HIV, the estimated incidence of undetected infection by serologic screening was 1 in 50,000 for normal risk potential donors and 1 in 11,000 for high risk potential donors; for HCV, undetected incidence by serologic screening was 1 in 5000 and 1 in 1000, respectively. Projected estimates of undetected infection with NAT screening versus serology alone suggest that NAT screening could significantly reduce the rate of undetected HCV for all donor risk strata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.